FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safetyMineo Matsumoto, Jean Sathish, Payal Arora et al.|Regulatory Toxicology and Pharmacology|2026Cited by 0